ELAN CORP. PLC agreed last week to sell its primary care franchise to King Pharmaceuticals Inc. for $850 million. The deal includes the US and Puerto Rican rights to Sonata (zaleplon) and Skelaxin (metaxalone).
Related Results
King backs out of Elan acquisition. (Breaking News Roundup). viagra. (King Pharmaceuti…
Cash-strapped Elan settles with King in dispute over drugs’ value
King completes Elan acquisition at discount.
American competition inquiry casts doubt over future of Elan
Elan sharpens focus with divestitures. (Markets: Life Sciences/Specialties).(…
King will acquire certain assets relating to Sonata, a nonbenzodiazepine hypnotic for the short-term treatment of insomnia, directly from Wyeth, which launched the drug in 1999. In late 2001, Elan assumed responsibility for the marketing Sonata in the US, and in the first nine months of …
Read the rest of this article with a Free Trial at HighBeam Research.